(0.33%) 5 116.53 points
(0.32%) 38 364 points
(0.37%) 15 987 points
(-0.98%) $83.03
(5.25%) $2.02
(0.32%) $2 354.70
(0.50%) $27.67
(4.12%) $960.05
(-0.27%) $0.932
(-0.48%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
@ $24.14
発行日: 15 2月 2024 @ 02:18
リターン: -25.81%
前回のシグナル: 2月 13 - 05:20
前回のシグナル:
リターン: -4.60 %
Live Chart Being Loaded With Signals
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...
Stats | |
---|---|
本日の出来高 | 33 293.00 |
平均出来高 | 246 262 |
時価総額 | 503.52M |
EPS | $0 ( 2024-04-03 ) |
Last Dividend | $0.188 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.66 |
ATR14 | $0.0390 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Kelley Erika K. | Buy | 0 | |
2024-02-20 | Minor Glenda J | Buy | 95 | Class A Common Stock |
2024-02-20 | Sutherlin Michael W | Buy | 406 | Class A Common Stock |
2024-02-20 | Shoemaker Leslie L | Buy | 43 | Class A Common Stock |
2024-02-20 | Jahnke David L | Buy | 515 | Class A Common Stock |
INSIDER POWER |
---|
-79.15 |
Last 94 transactions |
Buy: 7 552 389 | Sell: 18 343 130 |
ボリューム 相関
Radius Health Inc 相関
10 最も負の相関 | |
---|---|
ORRF | -0.913 |
SABS | -0.913 |
MMAC | -0.908 |
LUCD | -0.908 |
VIEW | -0.905 |
AMRB | -0.89 |
SGMA | -0.887 |
LCAP | -0.885 |
LGHL | -0.884 |
TRIT | -0.883 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Radius Health Inc 相関 - 通貨/商品
Radius Health Inc 財務諸表
Annual | 2023 |
収益: | $2.88B |
総利益: | $307.71M (10.68 %) |
EPS: | $-0.920 |
FY | 2023 |
収益: | $2.88B |
総利益: | $307.71M (10.68 %) |
EPS: | $-0.920 |
FY | 2022 |
収益: | $3.49B |
総利益: | $488.07M (14.00 %) |
EPS: | $6.01 |
FY | 2021 |
収益: | $229.97M |
総利益: | $210.82M (91.67 %) |
EPS: | $-1.484 |
Financial Reports:
No articles found.
Radius Health Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.188 | 2023-04-21 |
Last Dividend | $0.188 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-27 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $0.563 | -- |
Avg. Dividend % Per Year | 0.60% | -- |
Score | 3.79 | -- |
Div. Sustainability Score | 8.22 | |
Div.Growth Potential Score | 5.26 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.564 | 1.80% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00339 | 1.500 | 9.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00556 | 1.200 | 9.81 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0111 | 1.500 | -0.988 | -1.482 | [0.1 - 1] |
payoutRatioTTM | 2.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.927 | 0.800 | 5.36 | 4.29 | [1 - 3] |
quickRatioTTM | 0.883 | 0.800 | 9.51 | 7.61 | [0.8 - 2.5] |
cashRatioTTM | 0.0132 | 1.500 | -1.038 | -1.557 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.81 | -8.71 | [0 - 0.6] |
interestCoverageTTM | 2.18 | 1.000 | -0.303 | -0.303 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.45 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.501 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0989 | 1.000 | -1.685 | -1.685 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0117 | 1.000 | -1.766 | -1.766 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.392 | 1.000 | 8.93 | 8.93 | [0.2 - 2] |
assetTurnoverTTM | 1.639 | 0.800 | 2.41 | 1.926 | [0.5 - 2] |
Total Score | 8.22 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 48.50 | 1.000 | 5.20 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0111 | 2.50 | -0.635 | -1.482 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.64 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.873 | 1.500 | 7.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0602 | 1.000 | -0.994 | 0 | [0.1 - 0.5] |
Total Score | 5.26 |
Radius Health Inc
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。